ONO Pharmaceutical’s Phase III Study on Cenobamate: A Potential Game-Changer for Epilepsy Treatment

ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.

Study Overview: ONO Pharmaceutical Co. Ltd is conducting a Phase III study titled ‘ONO-2017 Phase III Study A Multicenter, Open-label Study in Japanese Patients With Primary Generalized Tonic Clonic Seizures.’ The study aims to evaluate the efficacy and safety of ONO-2017, in combination with other antiepileptic drugs, for treating Japanese patients suffering from generalized tonic-clonic seizures. This research is significant as it could lead to improved treatment options for epilepsy, a condition affecting many globally.

Intervention/Treatment: The study is testing an experimental drug called Cenobamate. This drug is administered orally once daily and is intended to enhance the treatment of generalized tonic-clonic seizures when used alongside existing antiepileptic medications.

Study Design: This interventional study follows a single-group model without any masking, meaning all participants receive the same treatment and both researchers and participants are aware of the treatment being administered. The primary purpose of the study is treatment-focused, aiming to assess the therapeutic benefits of Cenobamate.

Study Timeline: The study began on August 8, 2024, with a primary completion date yet to be announced. The most recent update was submitted on June 15, 2025. These dates are crucial for tracking the progress and expected completion of the study, which remains in the recruiting phase.

Market Implications: The ongoing study of Cenobamate by ONO Pharmaceutical could positively influence the company’s stock performance if results demonstrate significant efficacy and safety. Success in this trial may bolster investor confidence and position ONO favorably against competitors in the epilepsy treatment market, potentially leading to increased market share.

The study is currently ongoing, with further details available on the ClinicalTrials portal.